ASTRAZENECA PHARMA INDIA LTD. - 506820 - Outcome Of The Board Meeting Held On Monday, February 8, 2021
At the Board meeting of the Company held on Monday, February 8, 2021 the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended December 31, 2020. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated February 8, 2021 are enclosed herewith. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Astrazeneca Pharma India Limited Receives Import And Market Permission In Form CT-20 (Subsequent New Drug Approval) From The Drugs Controller General Of India For Dapagliflozin Tablets 10Mg
This is to inform that AstraZeneca Pharma India Limited has received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India for Dapagliflozin Tablets 10mg. Dapagliflozin Tablets 10mg is now approved for additional indication: For the treatment of patients of Chronic Kidney Disease up to Stage III (eGFR of greater than or equal to 30ml/min/1.73m2). The receipt of this permission paves way for the launch of Dapagliflozin Tablets 10mg into a new disease area to Nephrologists in India, subject to the receipt of related statutory approvals and licenses. Oxford says Covid-19 vaccine with AstraZeneca works against UK variant
The variant, first identified in Kent, southern England, is more easily transmissible, prompting many countries to restrict travel to Britain ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing a copy of newspaper advertisement published in Business Standard and Prajavani newspapers. Sputnik-AstraZeneca Covid-19 vaccine trials to start in Azerbaijan, MidEast
AstraZeneca said in December it would start clinical trials to test combining the two vaccines to see if this could boost the efficacy of the British shot. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015, the Company is intimating the request received relating to Loss of share certificate and issue of duplicate share certificate as per attached details.
COVID-19 Vaccine | AstraZeneca to supply 9 million more vaccine doses to European Union
European Commission President Ursula von der Leyen said after a call with seven vaccine makers Sunday that AstraZeneca will also begin deliveries one week sooner than scheduled and expand its manufacturing capacity in Europe Vietnam gives nod to AstraZeneca vaccine following new virus wave
AstraZeneca becomes the first coronavirus vaccine to be approved in the country ASTRAZENECA PHARMA INDIA LTD. - 506820 - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Monday, February 8, 2021
ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2021 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2020 We would also like to inform you that the 'Trading Window' remains closed for all Designated Persons, from December 16, 2020 to February 10, 2021 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015.
Supply of COVID-19 vaccines may meet, even outstrip demand in India by Q3: AstraZeneca chief
The pandemic has shown how resilient healthcare is, and how important pillar biopharmaceutical industry is as part of the healthcare ecosystem.